Centene (CNC) stock is in focus after the company moved to offer voluntary buyouts to most employees, a cost reduction step tied to weaker health plan membership, especially in Affordable Care Act marketplace products.

Despite the recent buyout announcement and a sharp pullback of nearly 4% on the day it was reported, Centene’s share price has a 90 day share price return of 77.38% and a 1 year total shareholder return of 10.64%. However, 3 and 5 year total shareholder returns remain negative, suggesting momentum has picked up recently after a weaker multi year stretch.

If Centene’s recent moves have you reassessing the sector, it could be a good moment to widen your search using a healthcare focused stock screener such as 41 healthcare AI stocks.

With Centene now trading close to its analyst price target and carrying mixed return figures over 3 and 5 years, the key question is whether recent momentum reflects a bargain valuation or whether the market is already pricing in future growth.

Most Popular Narrative: 11.1% Overvalued

The most followed narrative for Centene pegs fair value at $54.94, slightly below the last close of $61.02, setting up a valuation debate around future profitability.

Plans to reach breakeven in the Medicare Advantage segment by 2027 are fortified by operational efficiencies, such as reductions in SG&A and enhancements in STARS ratings, potentially improving future net margins.

Want to understand why this valuation leans cautious despite growth forecasts? The narrative rests on a carefully balanced mix of revenue growth, margin repair, and a future earnings multiple that is lower than many healthcare peers, yet still assumes a meaningful turnaround in profitability.

Result: Fair Value of $54.94 (OVERVALUED)

However, Centene’s story can shift quickly if Medicaid rate discussions turn less favorable or if Marketplace disenrollment and unpaid premiums affect revenue more than expected.

Another View: Centene’s Valuation Through Sales Multiples

While the most widely followed Centene narrative points to shares trading about 11.1% above its $54.94 fair value estimate, the market is putting a very different price on the company’s sales. Centene trades on a P/S ratio of 0.2x, compared with a fair ratio of 0.8x, the US Healthcare industry at 1.3x, and peer average at 1.6x. This implies investors are currently paying much less for each dollar of Centene’s revenue than for many competitors, so the key question is whether that discount reflects real business risk or a potential opportunity.

Next Steps

With sentiment on Centene split between risks and rewards, it makes sense to move quickly. Review the underlying numbers and test the theses yourself, then weigh the balance of potential upsides and concerns by checking the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Centene?

If Centene has sharpened your focus, do not stop here. Use these curated stock ideas to pressure test your thinking and uncover opportunities you might otherwise miss.

• Target potential value upside by scanning companies that combine quality fundamentals with appealing valuations through the 45 high quality undervalued stocks.
• Prioritize resilience and sleep better at night by reviewing companies highlighted in the 66 resilient stocks with low risk scores.
• Pursue future leaders early by hunting for underfollowed opportunities surfaced in the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.